The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | ALTA-1L: final overall survival results of brigatinib vs crizotinib for ALK+ lung cancer
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the overall survival results from the ALTA-1L trial (NCT02737501), which compared brigatinib to crizotinib as a first-line therapy for patients with ALK+ lung cancer. The median progression-free survival of brigatinib was 24 months, compared to 11 months for crizotinib, as assessed by a Blinded Independent Review Committee (BIRC). Crossover was built into the study, with 47% of patients receiving crizotinib switching over to brigatinib. Dr Popat highlights the potency of brigatinib in a post-crizotinib setting. The 4-year survival for patients treated with brigatinib was 66% compared to 60% for crizotinib. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
